Order:
  1.  69
    Mapping the Ethical Issues of Brain Organoid Research and Application.Tsutomu Sawai, Yoshiyuki Hayashi, Takuya Niikawa, Joshua Shepherd, Elizabeth Thomas, Tsung-Ling Lee, Alexandre Erler, Momoko Watanabe & Hideya Sakaguchi - 2022 - American Journal of Bioethics Neuroscience 13 (2):81-94.
    In 2008, researchers created human three-dimensional neural tissue – known as the pioneering work of “brain organoids.” In recent years, some researchers have transplanted human brain organoids into animal brains for applicational purposes. With these experiments have come many ethical concerns. It is thus an urgent task to clarify what is ethically permissible and impermissible in brain organoid research. This paper seeks (1) to sort out the ethical issues related to brain organoid research and application and (2) to propose future (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   32 citations  
  2.  53
    The deadly business of an unregulated global stem cell industry.Tamra Lysaght, Wendy Lipworth, Tereza Hendl, Ian Kerridge, Tsung-Ling Lee, Megan Munsie, Catherine Waldby & Cameron Stewart - 2017 - Journal of Medical Ethics 43 (11):744-746.
    In 2016, the Office of the State Coroner of New South Wales released its report into the death of an Australian woman, Sheila Drysdale, who had died from complications of an autologous stem cell procedure at a Sydney clinic. In this report, we argue that Mrs Drysdale's death was avoidable, and it was the result of a pernicious global problem of an industry exploiting regulatory systems to sell unproven and unjustified interventions with stem cells.
    Direct download (7 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  3.  36
    Conditional Approvals for Autologous Stem Cell–Based Interventions: Conflicting norms and institutional legitimacy.Tsung-Ling Lee & Tamra Lysaght - 2018 - Perspectives in Biology and Medicine 61 (1):59-75.
    Regulators around the world are coming under pressure from patients, clinicians, and industry groups to streamline the market approval process for highly novel biomedical technologies, including stem cells and regenerative medicine products. The rationale for streamlining this process centers on the perceived failures of regulatory systems to encourage biomedical innovation and provide patients with timely access to potentially beneficial yet experimental therapies. Critics claim that the process of generating scientific evidence in phased clinical trials is too costly, time-consuming, and poorly (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark